Stocktwits on MSN15h
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page
Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
Fintel on MSN1d
Leerink Partners Upgrades Regeneron Pharmaceuticals (REGN)
Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...
Regeneron upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $862.00 at Leerink Partners
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.
Leerink Partnrs Issues Positive Forecast for REGN Earnings
Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for Regeneron Pharmaceuticals in a note issued to ...
Jefferies Sticks to Their Buy Rating for Regeneron (REGN)
In a report released on February 3, Akash Tewari from Jefferies maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
AMD, Spotify downgraded: Wall Street's top analyst calls
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call
Marion McCourt; Executive Vice President - Commercial; Regeneron Pharmaceuticals Inc. Christopher Fenimore; Chief Financial Officer, Senior Vice President - Finance; Regeneron Pha ...